Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

127P - Stereotactic ablative radiotherapy and durvalumab: The backbone of unresectable locally advanced non-small cell lung cancer patients unfit to concurrent chemo-radiotherapy – Rib of START-NEW-ERA trial


31 Mar 2023


Poster Display session


Fabio Arcidiacono


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


F. Arcidiacono1, F. Trippa2, E. Maranzano2, M. Italiani2, M. Casale2, P. Anselmo3

Author affiliations

  • 1 Terni/IT
  • 2 "S.Maria" Hospital, Terni/IT
  • 3 "S.Maria" Hospital, 05100 - Terni/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 127P


Several real-world experiences have been reported safety and effectiveness of Durvalumab after concurrent or sequential chemo-radiotherapy (ChT-RT) in lLA-NSCLC patients. There is a lack of data after sequential ChT-hypofractionated RT. In single arm phase II trial (NCT05291780) we assessed local control (LC) and safety of stereotactic ablative radiotherapy (SAbR) in unresectable LA-NSCLC patients unfit for concurrent ChT-RT (1). Here we report clinical outcomes of SAbR in LA-NSCLC patients treated with radical-intent based on PACIFIC trial.


Between December 31, 2015 and June 30, 2022 71 LA-NSCLC patients were enrolled. 40 (56%) fit patients received neoadjuvant ChT and 15 (37%) received Durvalumab. The tumor volume included primary tumor (T) and any regionally positive node/s (N). The co-primary study endpoints were LC and safety.


The median age was 71 years (range, 52–78). Histology was adenocarcinoma (ADC) and squamous cell carcinoma (SCC) and in 9 (60%) and 6 (40%), respectively. The stage was IIIA, IIIB and IIIC in 7 (47%), 5 (33%) and 3 (20%) patients, respectively. Median prescribed dose was 45 Gy (range, 40–50) and 40 Gy (35–50) in 5 daily fractions to T and N, respectively. After a median follow-up of 16 months (range, 6–62), 4 (27%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7–34). The median LR-free survival (FS) was 34 months (95% CI, 14 to 34). The 1-, 2- and 4-year LR-FS rates were 92 ± 8%, 72 ± 14% and 48 ± 22%, respectively. At last follow-up, 23 (58%) patients were alive. Median overall survival (OS) was 50 months (95% CI, 31–55). The 1, 2, and 4-year OS rates were 92 ± 5%, 70 ± 8% and 51 ± 9%, respectively. 7 patients had disease recurrence, 4 and 3 during and after completion of Durvalumab. 2(13%) discontinued Durvalumab due to G3 toxicity.


SABR and immunotherapy can be the backbone of patients unfit to concurrent ChT-RT. Our early outcomes would suggest the feasibility of using this approach in LA-NSCLC patients unfit for concurrent ChT-RT.

Int J Radiat Oncol Biol Phys. 2022 Oct 24;S0360–3016(22)03459–9. doi: 10.1016/j.ijrobp.2022.10.025.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.